Mayoly Spindler announces that on April 3rd, Ms Clotilde Clément joined Mayoly Spindler as Director of Regulatory Affairs and Responsible Pharmacist, Executive Committee member.
Clotilde is a Pharmacist with an advanced degree in Health Law, and comes to us with broad experience in the pharmaceutical industry, including the last ten years heading up Regulatory Affairs at Sandoz. An elected member of the National Order of Pharmacists, Clotilde was also Regulatory Affairs Director at Gemme (Association of pharma professionals in generics and biosimilars) and brings solid expertise in all aspects of the Regulatory function.
There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.
BROOKLYN, N.Y., 17 NOV. 2016 (GLOBE NEWSWIRE) ‐‐ AZURRX BIOPHARMA INC. (NASDAQ:AZRX)
(“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).
The open-label, dose escalation Phase II study is being conducted in two sites in Australia
The Royal Adelaide Hospital and Linear Clinical Research in Perth as well as two sites in New Zealand, P3 Research in Wellington and CCST in Christchurch. The study is projected to enroll approximately 12 patients with EPI caused by chronic pancreatitis over the next several months. Dr. Quoc Nam Ngyuen, Associate Professor in the Department of Gastroenterology at the Royal Adelaide Hospital is the principal investigator for the study.
The primary objective of this Phase II study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Initial study results from the MS1819-SD Phase II study are expected in the first half of 2017.
Paris, Wednesday, October 5, 2016
MAYOLY SPINDLER acquires the Swedish laboratory Kibion and becomes the leading company in the market of detecting and control of Helicobacter pylori infections.
|Mayoly Spindler, the independent French benchmark laboratory in gastroenterology and dermocosmetics, is continuing its international development with the acquisition of the young Swedish laboratory Kibion. Mayoly Spindler has there by become the leading company in the market of urea breath tests used to diagnose the presence of Helicobacter pylori and control its eradication.
>Press release in english
18 October 2016 was the fourth award ceremony of Allure Russia Best of Beauty 2016 where 246 Awards found brands-winners!
From September 2015 to September 2016 editorial staff and experienced experts tested 1700 cosmetic products from different brands and selected the best in its category!
Face, body and hair masks, serums and creams, bath products, beach and make-up!
For the first time at the fourth annual nominations were submitted-category “Pharma-Beauty”, where
SOS Repair body Cream won its Award!!!!
We are the best drugstore cream according to the magazine Allure!!!
But! That’s not all!
We also received the award HALL OF FAME, which was rated only 4 products in category of “Pharma-beauty”, as the products apart from the competition!
We congratulate everybody with such an important first victory!
Magazine’s circulation: 180 000 copies
Audience: 300 900 people
Date/output frequency 12 times a year in the 20’s of every month.